ICG144

**ICG144** is an investigational, lentivirally engineered compound chimeric antigen receptor T-cell therapy for relapsed or refractory high-risk hematologic malignancies, principally acute myeloid leukemia. The product expresses two complete CAR constructs linked by a self-cleaving P2A peptide: an anti-CLL1 CAR designed to address leukemia stem cell populations and an anti-CD33 CAR directed at bulk AML blasts. The CLL1 CAR incorporates CD28 costimulation, while the CD33 CAR incorporates 4-1BB costimulation; both use CD3ζ signaling. The construct also includes a CD52-based safety switch intended to permit pharmacologic elimination of infused CAR-T cells with alemtuzumab if required. ICG144 was evaluated in the phase 1 NCT03795779 study. ([library.ehaweb.org](https://library.ehaweb.org/eha/2020/eha25th/294969/fang.liu.first-in-human.cll1-cd33.compound.car.28ccar29.t.cell.therapy.in.html))

Other names

CLL1-CD33 cCARCLL-1-CD33 cCARCLL 1-CD33 cCARCLL1-CD33 cCAR T cellsCLL-1-CD33 cCAR T cellsCLL 1-CD33 cCAR T cellsCLL1-CD33 compound CAR T cellsCLL-1-CD33 compound CAR T cellsCLL 1-CD33 compound CAR T cellsCLL1b-CD33b cCARCLL-1b-CD33b cCARCLL 1b-CD33b cCAR